Introduction and TP53 Background in EGFR-Mutant NSCLC

Dr. Estelamari Rodriguez introduces a discussion focused on TP53 mutations as treatment selection biomarkers in first-line EGFR-mutant non-small cell lung cancer (NSCLC), joined by Dr. Coral Olazagasti from the University of Miami. The conversation centers on integrating the recently presented TOP study results within the broader treatment landscape alongside FLAURA2 and MARIPOSA data.

TP53 mutations occur in 40% to 70% of patients with EGFR-mutant disease and have long been recognized as negative prognostic factors. Prior to the TOP study, clinicians relied on retrospective analyses and biological understanding of TP53's poor prognostic implications when making treatment intensification decisions.

Dr. Olazagasti notes that before formal data, treatment discussions often focused on patients with high-risk features including TP53mutations, brain metastases, and high disease burden as potential candidates for combination therapy. However, these recommendations were largely hypothetical, based on historical understanding of TP53 biology rather than prospective evidence.

The panelists emphasize that many physicians already suspected TP53-mutant patients would benefit from combination approaches, given the established bias that targeting TP53 requires chemotherapy intervention. The TOP study provides crucial evidence supporting these clinical intuitions with definitive data demonstrating treatment intensification benefits in this population.

This prospective validation represents a significant advancement from post-hoc subgroup analyses that characterized previous studies, where TP53 status was determined through circulating tumor DNA in select patient subsets rather than systematic tissue-based testing across the entire study population.